Shattuck Labs to Present at TIGIT Therapies Digital Summit 2021

Rhea-AI Summary

Shattuck Labs, a clinical-stage biotechnology company (NASDAQ: STTK), is set to present at the TIGIT Therapies Digital Summit 2021 from December 7-9. CEO Taylor Schreiber will present on December 9 at 9:30 a.m. EST, discussing TIGIT blockade in refractory tumors. Shattuck is advancing bi-functional fusion proteins targeting cancer and autoimmune diseases, with three ongoing Phase 1 trials. The presentation will be available for download on the company's website and to registered participants of the summit.

AUSTIN, TX and DURHAM, NC, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced its presentation at the TIGIT Therapies Digital Summit 2021 being held virtually December 7 – 9, 2021.

Presentation Details
Presentation Title: LIGHTing the Way for TIGIT Blockade in CPI Refractory Tumors
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: December 9, 2021
Time: 9:30 a.m. EST
Location: https://tigit-therapies.com/

The presentation will be available for download on the Events & Presentations section of the company’s website and also will be available to registered participants of the TIGIT Therapies Digital Summit 2021.

About Shattuck Labs, Inc.

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com 

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com

FAQ

What is Shattuck Labs presenting at the TIGIT Therapies Digital Summit 2021?

Shattuck Labs will present 'LIGHTing the Way for TIGIT Blockade in CPI Refractory Tumors' at the TIGIT Therapies Digital Summit on December 9, 2021.

When is Shattuck Labs' presentation at the TIGIT Therapies Digital Summit?

The presentation is scheduled for December 9, 2021, at 9:30 a.m. EST.

Where can I find Shattuck Labs' TIGIT summit presentation?

The presentation will be available for download on Shattuck Labs' website and to registered summit participants.

What is the focus of Shattuck Labs' clinical trials?

Shattuck Labs is focused on developing bi-functional fusion proteins for cancer and autoimmune disease treatment, with three ongoing Phase 1 clinical trials.

What is the stock symbol for Shattuck Labs?

The stock symbol for Shattuck Labs is STTK.